Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,458 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Tumor, Adult Clear all
Terminated Phase 1 Interventional

A Study to Investigate LYL845 in Adults With Solid Tumors

NCT05573035
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
LYL845
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Sacramento, California • Santa Monica, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

NCT00553189
View directory record Official record
Conditions
Solid Tumors, Lymphomas
Interventions
ABT-888, Topotecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors

NCT00541138
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, tamoxifen citrate, topotecan hydrochloride, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

NCT00004914
View directory record Official record
Conditions
Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa, physical therapy
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Solid Tumors

NCT00003250
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fenretinide
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

NCT00813384
View directory record Official record
Conditions
Cancer, Oncology, Tumors, Advanced Malignancy, Advanced Solid Tumors, Oncology Patients
Interventions
AMG 208
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Beverly Hills, California • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 4, 2026, 5:45 PM EDT
Active, not recruiting Phase 1 Interventional

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

NCT02432963
View directory record Official record
Conditions
Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 4, 2026, 5:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions
ALE.P03
Drug
Lead sponsor
Alentis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma

NCT00589381
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fenretinide lipid matrix
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 4, 2026, 5:45 PM EDT
Recruiting No phase listed Observational

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

NCT02215928
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
mutation analysis, cytology specimen collection procedure, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 4, 2026, 5:45 PM EDT
Recruiting Phase 1 Interventional

Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

NCT05055609
View directory record Official record
Conditions
Solid Tumor, Adult, Oncology
Interventions
TRE-515
Drug
Lead sponsor
Trethera
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Santa Monica, California • Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 4, 2026, 5:45 PM EDT
Terminated Phase 1 Interventional

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

NCT01159301
View directory record Official record
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Myeloid Leukemia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
entinostat, sorafenib tosylate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 4, 2026, 5:45 PM EDT
Active, not recruiting Phase 1 Interventional

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT03618381
View directory record Official record
Conditions
Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma
Interventions
second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

NCT02775292
View directory record Official record
Conditions
Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Nivolumab, NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL, NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine, Positron Emission Tomography
Biological · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors

NCT00287937
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vorinostat, paclitaxel, carboplatin, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors

NCT00098501
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pelitinib, temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 4, 2026, 5:45 PM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00016172
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pegylated liposomal doxorubicin hydrochloride, picoplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy

NCT00004926
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vitamin D3 analogue ILX23-7553
Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
2
States / cities
Newark, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 4, 2026, 5:45 PM EDT
Terminated Phase 1 Interventional

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

NCT05381909
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
BGB-24714, Paclitaxel, Carboplatin, Docetaxel
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Gilbert, Arizona • Sarasota, Florida • St. Petersburg, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

NCT00825487
View directory record Official record
Conditions
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Interventions
ARQ 621
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Phoenix, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2011 · Synced Oct 4, 2026, 5:45 PM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Solid Tumors

NCT00009932
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, fenretinide, paclitaxel
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 4, 2026, 5:45 PM EDT
Recruiting Phase 1 Interventional

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

NCT04412616
View directory record Official record
Conditions
Advanced EGFR Positive Solid Tumor
Interventions
ZZ06
Biological
Lead sponsor
Changchun Intellicrown Pharmaceutical Co. LTD
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Fairway, Kansas • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 4, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors

NCT01450384
View directory record Official record
Conditions
Unspecified Adult Solid Tumor
Interventions
sorafenib tosylate, pemetrexed disodium, laboratory biomarker analysis, biopsy
Drug · Other · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 4, 2026, 5:45 PM EDT